	VL>1,000 vs ≤1,000 (Copies/mL)	VL>40 vs ≤40 (Copies/mL)	VL>1,000 vs VL>40 and ≤1,000 (Copies/mL)
Age (Per 10 years older)	0.68 (0.51, 0.89)*	0.83 (0.67, 1.03)	0.73 (0.54, 0.99)
Male vs. Female	0.80 (0.49, 1.3)	0.73 (0.49, 1.1)	0.97 (0.54, 1.73)
WHO Stage 2 ^b	0.56 (0.22, 1.46)	1.07 (0.52, 2.21)	0.43 (0.14, 1.31)
WHO Stage 3 ^b	1.29 (0.63, 2.64)	1.45 (0.79, 2.67)	1.00 (0.41, 2.44)
WHO Stage 4 ^b	0.52 (0.21, 1.28)	0.87 (0.44, 1.74)	0.46 (0.16, 1.34)
TB treatment on 2nd line	2.64 (1.23, 5.70)*	1.76 (0.83, 3.73)	2.50 (0.94, 6.66)
Per Year Longer on 1st line	1.13 (0.99, 1.30)	1.04 (0.93, 1.16)	1.18 (0.99, 1.41)
Per Year Longer on 2nd line	0.83 (0.72, 0.95)	0.87 (0.79, 0.96)	0.88 (0.75, 1.03)
Complete One Month Adherence vs. Incomplete	0.58 (0.17, 1.93)	0.80 (0.26, 2.43)	0.55 (0.12, 2.54)
Complete 7-day Adherence vs. Incomplete	0.73 (0.28, 1.91)	2.25 (0.90, 5.59)	0.12 (0.01, 0.99)
Per 100 cell higher CD4 Count	0.69 (0.59, 0.82)*	0.80 (0.72, 0.89)*	0.78 (0.65, 0.94)*
Per 1 unit higher CD4 Percent	0.93 (0.89, 0.96)	0.94 (0.91, 0.96)	0.95 (0.91, 0.99)
TI on 1st line vs. No TI	1.77 (0.88, 3.57)	1.39 (0.74, 2.63)	1.68 (0.71, 3.97)
TI on 2nd line vs No TI	1.95 (0.57, 6.64)	1.06 (0.34, 3.36)	2.74 (0.49, 15.36)
TI between 1st and 2nd line vs No TI	2.66 (0.92, 7.70)	1.62 (0.57, 4.65)	2.79 (0.68, 11.50)
Unique ARV regimen	1.96 (0.65, 5.90)	1.22 (0.44, 3.44)	2.29 (0.53, 9.89)
>1 1st line regimens vs. 1	0.76 (0.45, 1.26)	0.68 (0.45, 1.02)	0.97 (0.53, 1.77)
>1 2nd line regimen vs. 1	0.97 (0.54, 1.72)	0.92 (0.58, 1.47)	1.03 (0.52, 2.03)
Pregnancy vs. None ^c	2.54 (1.32, 4.89)	1.28 (0.76, 2.17)	3.03 (1.36, 6.77)
pMTCT vs. None	0.16 (0.02, 1.30)	1.06 (0.34, 3.31)	0.08 (0.01, 0.77)

Supplementary Table 1: Correlates of viral load failure according to viral load threshold ^a

<u>Footnote:</u> ^a Odds Ratio (95% Confidence Interval) from unadjusted logistic regression analyses; ^b WHO Stage 1 Reference; ^c Among those with any pregnancy. Abbreviations: ARV, antiretroviral; pMTCT, prevention of mother to child transmission TB, tuberculosis; TI, treatment interruption; VL, viral load; WHO, World Health Organization. * Remained significant (p<0.05) in a multivariable logistic regression model that included age, TB treatment on 2nd-line, time on 2nd line and CD4 count.

	Total Cohort (n=109)	No Sequence (n=74)	Sequence Available (n=35)	p-value			
Continuous Variables: Median (range)							
Age	41 (22, 72)	41 (29, 72)	43 (22, 69)	0.889			
Years on 1st line	2.7 (0.6, 10.39)	2.61 (0.6, 8.05)	2.77 (0.84, 10.39)	0.372			
Years on 2nd line	1.82 (0.44, 7.52)	2.21 (0.45, 7.52)	1.59 (0.44, 7.45)	0.379			
CD4 Count (cells/µL)	278 (31, 1377)	284 (39, 1377)	241 (31, 740)	0.179			
CD4 Percent: median	16 (2, 36)	16 (5, 36)	14 (2, 28)	0.158			
VL (Log10 Copies/mL)	2.13 (1.61, 3)	2.09 (1.61, 2.97)	2.18 (1.62, 3)	0.494			
Categorical Covariates: number, %							
Male	47, 43%	29, 39%	18, 51%	0.301			
WHO Stage 1	12, 11%	7, 10%	5, 15%	0.599			
WHO Stage 2	21, 20%	14, 19%	7, 21%	-			
WHO Stage 3	50, 47%	37, 51%	13, 38%	-			
WHO Stage 4	24, 22%	15, 21%	9, 26%	-			
TB Treatment on 2nd Line	7, 6%	5, 7%	2, 6%	1.000			
Incomplete 1-month adherence	3, 3%	2, 3%	1, 3%	1.000			
Incomplete 7-day adherence	1, 1%	1, 1%	0, 0%	1.000			
TI on 1st Line	11, 10%	9, 12%	2, 6%	0.497			
TI on 2nd Line	2, 2%	2, 3%	0, 0%	1.000			
TI between 1st and 2nd Line	3, 3%	3, 4%	0, 0%	0.550			
Unique ARV Regimen	3, 3%	3, 4%	0, 0%	0.550			
>One First-Line Regimen	38, 35%	24, 32%	14, 40%	0.519			
>One 2 nd -Line Regimen	25, 23%	19, 26%	6, 17%	0.716			
Previous Pregnancies ^b	18, 29%	11, 24%	7, 41%	0.216			


<u>Supplementary Table 2</u>: Characteristics of patients with and without sequences at $VL \le 1,000$ copies/mL^a.

<u>Footnote:</u> ^a Measures presented as *median (range)* for continuous and *n*, % for categorical measures. P-values are from Wilcoxon Rank Sum for continuous measures and Fisher exact tests for categorical measures. ^b Pregnancy history unknown for 2/62. Abbreviations: ARV, antiretroviral; TB, tuberculosis; TI, treatment interruption; VL, viral load; WHO, World Health Organization.

Supplementary Table 3: Characteristics of patients with and without sequences at
VL>1,000 copies/mL ^a .

	Total Cohort (n=82)	Sequence Available (n=70)	No Sequence (n=12)	p-value
Continuous Covariates: mediar	n (range)			
Age	38.84 (18.64, 69.84)	39.07 (18.64, 63.8)	38.22 (21, 69.84)	0.995
Years on 1st line	3.30 (0.74, 8.67)	3.34 (0.74, 8.67)	3.05 (1.17, 7.02)	0.475
Years on 2nd line	1.29 (0.46, 7.24)	1.36 (0.46, 7.24)	1.23 (0.59, 5.38)	0.995
CD4 Count (cells/µL)	171.5 (8, 855)	170.5 (8, 855)	210 (69, 748)	0.352
CD4 Percent	14 (1, 35)	13.5 (1, 35)	16 (6, 24)	0.490
VL (Log ₁₀ Copies/mL)	3.73 (3.01, 6.53)	3.95 (3.01, 6.53)	3.13 (3.04, 3.76)	<0.001
Categorical Covariates: numbe	r, %			
Male	36, 44%	30, 43%	6, 50%	0.756
WHO Stage 1	12, 15%	11, 16%	1, 8%	0.223
WHO Stage 2	9, 11%	8, 11%	1, 8%	-
WHO Stage 3	50, 61%	44, 63%	6, 50%	-
WHO Stage 4	11, 13%	7, 10%	4, 33%	-
TB Treatment on 2nd Line	12, 15%	10, 14%	2, 17%	1.000
Incomplete 1-month adherence	4, 5%	4, 6%	0, 0%	1.000
Incomplete 7-day adherence	6, 7%	5, 7%	1, 8%	0.626
TI on 1st Line	13, 16%	11, 16%	2, 17%	1.000
TI on 2nd Line	4, 5%	4, 6%	0, 0%	1.000
TI between 1st and 2nd Line	6, 7%	5, 7%	1, 8%	1.000
Unique ARV Regimen	5, 6%	5, 7%	0, 0%	1.000
>One First-Line Regimen	28, 34%	22, 31%	6, 50%	0.343
>One 2 nd -Line Regimen	19, 23%	16, 23%	3, 25%	0.362
Previous Pregnancies	26, 57%	21, 52%	5, 83%	0.212

<u>Footnote:</u> ^a Measures presented as *median (range)* for continuous and *n*, % for categorical measures. P-values are from Wilcoxon Rank Sum for continuous measures and Fisher exact tests for categorical measures. Abbreviations: ARV, antiretroviral; TB, tuberculosis; TI, treatment interruption; VL, viral load; WHO, World Health Organization.






Figure Legend

<u>Supplementary Figure 1:</u> The figure presents frequencies of mutations (Y axis) at positions associated with resistance to NRTIs (left mutation block, X axis); NNRTIs (middle block) and PIs (right block), in patients with VL>1,000 copies/ML (gray) and VL≤1,000 copies/mL (black).